Abstract Body

Residual viremia (RV; <50 c/ml HIV RNA) persists in up to 70-90% patients under successful cART over extended periods. Its role in loss of virologic control is controversial, since it has been found to predict virological rebound in some, but not all studies. Further, RV dynamics are still largely unknown. Our aim was to monitor RV in effectively cART-treated patients for one year after viral suppression (VS; <50 c/ml) to assess the proportion of patients reaching ultra-deep suppressed viremia (USV; <5 c/ml) and the ability to maintain this condition.

Sixty HIV-infected patients (49 with chronic HIV infection, 11 with primary HIV infection) on first-line cART, reaching and maintaining stable VS, were analysed (M/F 54/6; mean age 36 y; pre-cART median HIV RNA 4.89 log10 c/ml and mean CD4+ 382/mm3). HIV RNA viral load (VL) and RV were measured with standard and ultrasensitive (US) protocols of Abbott Real-Time HIV-1 assay (LLOD: 40 and 5 c/ml, respectively) at baseline (BL), at VS (T0), at month 6 (T1) and 12 (T2) after T0. Cox proportional hazard models were carried out to analyze factors associated with time to first USV and USV maintenance.

Overall, during first year of cART-induced continuous VS, a steady decrease of the median RV occurred: median RV log10 c/ml (IQR) at T0, T1 and T2 were 0.81 (0.40-1.23), 0.39 (0.00-0.78) and 0.18 (0.00-0.068), respectively. A significant difference was found for T0 vs T1 and To vs T2: p<0.0005. All patients achieved USV: 27 (45%) maintained USV throughout the study and, among them, 88.2% showed undetected HIV RNA with US at the end of follow-up. The remaining 33 patients, although with continuous VS, showed fluctuating levels of RV between 5-10 c/ml HIV RNA. Factors associated with the inability to maintain USV were [aHR, 95%IC]: pre-cART higher VL [2.14, 1.23-3.72], pre-cART CD4+ <200/mm3 [3.97, 1.61-9.77], >12 weeks to achieve VS [2.51, 1.07-5.89] (Figure).

After VS on first-line cART, a steady and significant reduction of RV is observed, suggesting progressive purging of viral reservoirs. In almost half of successfully-treated patients, USV is achieved and maintained throughout the first year of continuous VS. Pre-cART lower VL and higher CD4+ cells, together with faster VS achievement, were all associated to USV attainment. Early start of cART and use of potent cART are essential to lower RV and viral reservoirs in HIV-positive patients.